Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records.

He KY, Zhao Y, McPherson EW, Li Q, Xia F, Weng C, Wang K, He MM.

PLoS One. 2016 Dec 8;11(12):e0167847. doi: 10.1371/journal.pone.0167847. eCollection 2016.

2.

Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b.

Mogilyansky E, Clark P, Quann K, Zhou H, Londin E, Jing Y, Rigoutsos I.

Front Genet. 2016 Aug 31;7:143. doi: 10.3389/fgene.2016.00143. eCollection 2016.

3.

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.

De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.

Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.

4.

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Prakash R, Zhang Y, Feng W, Jasin M.

Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4):a016600. doi: 10.1101/cshperspect.a016600. Review.

5.

Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S.

Gastroenterology. 2015 Mar;148(3):556-64. doi: 10.1053/j.gastro.2014.11.042. Epub 2014 Dec 2.

6.

Familial and sporadic pancreatic cancer share the same molecular pathogenesis.

Norris AL, Roberts NJ, Jones S, Wheelan SJ, Papadopoulos N, Vogelstein B, Kinzler KW, Hruban RH, Klein AP, Eshleman JR.

Fam Cancer. 2015 Mar;14(1):95-103. doi: 10.1007/s10689-014-9755-y.

7.

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.

Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.

Br J Cancer. 2014 Sep 9;111(6):1132-8. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.

8.

Elevated DNA damage response in pancreatic cancer.

Osterman M, Kathawa D, Liu D, Guo H, Zhang C, Li M, Yu X, Li F.

Histochem Cell Biol. 2014 Dec;142(6):713-20. doi: 10.1007/s00418-014-1245-7. Epub 2014 Jul 8.

9.

Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma.

Reznik R, Hendifar AE, Tuli R.

Front Physiol. 2014 Mar 3;5:87. doi: 10.3389/fphys.2014.00087. eCollection 2014. Review.

10.

Screening and early detection of pancreatic cancer in high risk population.

Chang MC, Wong JM, Chang YT.

World J Gastroenterol. 2014 Mar 7;20(9):2358-64. doi: 10.3748/wjg.v20.i9.2358. Review.

11.

Familial pancreatic cancer: genetic advances.

Rustgi AK.

Genes Dev. 2014 Jan 1;28(1):1-7. doi: 10.1101/gad.228452.113. Review.

12.

Recent progress in pancreatic cancer.

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH.

CA Cancer J Clin. 2013 Sep;63(5):318-48. doi: 10.3322/caac.21190. Epub 2013 Jul 15. Review.

13.

Pancreatic cancer genomics: insights and opportunities for clinical translation.

Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA.

Genome Med. 2013 Mar 28;5(3):26. doi: 10.1186/gm430. eCollection 2013. Review.

14.

High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.

Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H.

Clin Cancer Res. 2013 Jul 1;19(13):3396-403. doi: 10.1158/1078-0432.CCR-12-3020. Epub 2013 May 8.

15.

Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.

Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.

16.

Pancreatic cancer screening.

Shin EJ, Canto MI.

Gastroenterol Clin North Am. 2012 Mar;41(1):143-57. doi: 10.1016/j.gtc.2011.12.001. Epub 2012 Jan 5. Review.

17.

Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers.

Amin S, McBride RB, Kline JK, Mitchel EB, Lucas AL, Neugut AI, Frucht H.

Cancer. 2012 Mar 1;118(5):1244-51. doi: 10.1002/cncr.26414. Epub 2011 Sep 1.

18.

Molecular characteristics of pancreatic ductal adenocarcinoma.

Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ.

Patholog Res Int. 2011 Mar 27;2011:620601. doi: 10.4061/2011/620601.

19.

Pathology of hereditary breast cancer.

van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19. Review.

20.

Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.

Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ.

Gastroenterology. 2011 Apr;140(4):1303-1313.e1-3. doi: 10.1053/j.gastro.2010.12.039. Epub 2011 Jan 1.

Supplemental Content

Support Center